Pertuzumab Vs. Pyrotinib in Combination With Trastuzumab and Taxanes for First-Line Treatment of HER2+ MBC: A Multicenter Real-World Study.

Cancer Med · 2026 · PMC13239294 · PMID 42162577

Europe PMC DOI

hedged sentences

0.0620

closest p · 1.2× alpha

0.0620

boldest claim

The sentences

showed a trendp = 0.062so close (0.05 < p ≤ 0.1)

Conversely, in those without prior therapy, THPy showed a trend toward PFS benefit (23.6 vs. 16.3 months, HR = 0.69, 95% CI: 0.46–1.02, p = 0.062) (Figure 2F ).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

provided preliminary insights, it was limited by a small sample size, did not reach statistical significance for the primary endpoint, and failed to provide an in‐depth analysis of the characteristics of beneficiary subgroups.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.